Pages that link to "Q28469062"

The following pages link to A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya (Q28469062):

Displaying 50 items.

• Advances and challenges in malaria vaccine development (Q21032463) ‎ (← links)
• A review of malaria vaccine clinical projects based on the WHO rainbow table (Q21034112) ‎ (← links)
• Immunoregulation in human malaria: the challenge of understanding asymptomatic infection (Q26775212) ‎ (← links)
• The evolution of poxvirus vaccines (Q26995905) ‎ (← links)
• Characterisation of Plasmodium invasive organelles; an ookinete microneme proteome (Q27972689) ‎ (← links)
• Modified Vaccinia Virus Ankara (Q28223836) ‎ (← links)
• Clearance of asymptomatic P. falciparum Infections Interacts with the number of clones to predict the risk of subsequent malaria in Kenyan children (Q28477259) ‎ (← links)
• Identification of targets of CD8⁺ T cell responses to malaria liver stages by genome-wide epitope profiling (Q28704543) ‎ (← links)
• Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection (Q28742762) ‎ (← links)
• Micro-epidemiological structuring of Plasmodium falciparum parasite populations in regions with varying transmission intensities in Africa (Q29464553) ‎ (← links)
• Novel viral vectored vaccines for the prevention of influenza (Q30418570) ‎ (← links)
• Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya (Q33294698) ‎ (← links)
• Defining childhood severe falciparum malaria for intervention studies (Q33294896) ‎ (← links)
• Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial (Q33317265) ‎ (← links)
• Helminth infection and eosinophilia and the risk of Plasmodium falciparum malaria in 1- to 6-year-old children in a malaria endemic area (Q33319239) ‎ (← links)
• Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). (Q33320536) ‎ (← links)
• Interactions between age and ITN use determine the risk of febrile malaria in children (Q33520924) ‎ (← links)
• Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model (Q33587443) ‎ (← links)
• Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya (Q33631268) ‎ (← links)
• Defining clinical malaria: the specificity and incidence of endpoints from active and passive surveillance of children in rural Kenya (Q33778747) ‎ (← links)
• Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease (Q33821137) ‎ (← links)
• Advances and challenges in malaria vaccine development. (Q34145333) ‎ (← links)
• Estimating individual exposure to malaria using local prevalence of malaria infection in the field (Q34221250) ‎ (← links)
• Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II. (Q34260750) ‎ (← links)
• Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations (Q34301461) ‎ (← links)
• Plasmodium immunomics. (Q34419934) ‎ (← links)
• The ratio of monocytes to lymphocytes in peripheral blood correlates with increased susceptibility to clinical malaria in Kenyan children (Q34600408) ‎ (← links)
• Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized (Q34612788) ‎ (← links)
• Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults (Q34634002) ‎ (← links)
• A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. (Q34734075) ‎ (← links)
• A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants (Q35036289) ‎ (← links)
• Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion (Q35113336) ‎ (← links)
• Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. (Q35571248) ‎ (← links)
• Estimation of vaccine efficacy in a repeated measures study under heterogeneity of exposure or susceptibility to infection (Q35581701) ‎ (← links)
• Malaria eradication and elimination: views on how to translate a vision into reality (Q35712522) ‎ (← links)
• Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector (Q35741984) ‎ (← links)
• Wind direction and proximity to larval sites determines malaria risk in Kilifi District in Kenya (Q35799032) ‎ (← links)
• Strategies for developing multi-epitope, subunit-based, chemically synthesized anti-malarial vaccines (Q35862464) ‎ (← links)
• A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria (Q35927866) ‎ (← links)
• Ex vivo monitoring of antigen-specific CD4+ T cells after recall immunization with tetanus toxoid. (Q36095146) ‎ (← links)
• Experimental Immunization Based on Plasmodium Antigens Isolated by Antibody Affinity. (Q36204459) ‎ (← links)
• Incorporating a quiz into informed consent processes: qualitative study of participants' reactions (Q36389400) ‎ (← links)
• Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults (Q36393102) ‎ (← links)
• Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity". (Q36394177) ‎ (← links)
• Malaria treatment with atovaquone-proguanil in malaria-immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malaria (Q36538784) ‎ (← links)
• Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A (Q36540068) ‎ (← links)
• Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans (Q36571340) ‎ (← links)
• Effect of Haemophilus influenzae type b vaccination without a booster dose on invasive H influenzae type b disease, nasopharyngeal carriage, and population immunity in Kilifi, Kenya: a 15-year regional surveillance study (Q36605757) ‎ (← links)
• Pre-erythrocytic malaria vaccines: identifying the targets (Q36644236) ‎ (← links)
• Vaccines against malaria - an update (Q36933780) ‎ (← links)